Show simple item record

Case report and literature review: transient Inab phenotype and an agglutinating anti-IFC in a patient with a gastrointestinal problem

dc.contributor.authorYazer, Mark H.en_US
dc.contributor.authorJudd, W.  Johnen_US
dc.contributor.authorDavenport, Robertson D.en_US
dc.contributor.authorDake, Louann R/en_US
dc.contributor.authorLomas-Francis, Christineen_US
dc.contributor.authorHue-Roye, Kimen_US
dc.contributor.authorPowell, Vivienen_US
dc.contributor.authorReid, Marion E.en_US
dc.date.accessioned2010-06-01T18:47:48Z
dc.date.available2010-06-01T18:47:48Z
dc.date.issued2006-09en_US
dc.identifier.citationYazer, Mark H.; Judd, W. John; Davenport, Robertson D.; Dake, Louann R.; Lomas-Francis, Christine; Hue-Roye, Kim; Powell, Vivien; Reid, Marion (2006). "Case report and literature review: transient Inab phenotype and an agglutinating anti-IFC in a patient with a gastrointestinal problem." Transfusion 46(9): 1537-1542. <http://hdl.handle.net/2027.42/71992>en_US
dc.identifier.issn0041-1132en_US
dc.identifier.issn1537-2995en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71992
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16965581&dopt=citationen_US
dc.description.abstractThe Inab phenotype is a rare deficiency of all Cromer antigens. These antigens are carried on the decay-accelerating factor (DAF, CD55) molecule that is attached to the red blood cell (RBC) membrane by a glycosylphosphatidylinositol (GPI) anchor. Although typically inherited, an acquired and transient form of the Inab phenotype also exists. A patient with the triad of transient Inab phenotype, a direct-agglutinating anti-IFC, and gastrointestinal (GI) abnormalities is reported. CASE REPORT: An 18-month-old boy with gastroesophageal reflux disease requiring a feeding tube, milk and soy intolerance, and severe growth retardation, as well as vision and hearing deficits from cytomegalovirus infection, was identified when pretransfusion testing revealed a potent panagglutinin (titer > 2000 at 4°C). This antibody did not react with Dr(a–) and IFC RBCs, and the autocontrol was negative. The patient’s RBCs lacked CD55 by flow cytometric techniques but had normal levels of CD59 and antigens such as Yt a and Emm, carried on GPI-linked proteins, thus excluding paroxysmal nocturnal hemoglobinuria. Several months after initial detection, the anti-IFC was virtually undetectable and his cells reacted weakly with anti-IFC, anti-Dr a , and anti-CD55. RBCs from the propositus’ parents and brother demonstrated normal CD55 and CD59 expression. CONCLUSION: This is the first example of a direct-agglutinating anti-IFC. The cause of the transient depression in CD55 protein (and thus Cromer system antigens) and appearance of anti-IFC remains unknown, as does the relationship between the patient’s GI system abnormalities and these serologic findings.en_US
dc.format.extent101796 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights2006 American Association of Blood Banksen_US
dc.titleCase report and literature review: transient Inab phenotype and an agglutinating anti-IFC in a patient with a gastrointestinal problemen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid16965581en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71992/1/j.1537-2995.2006.00933.x.pdf
dc.identifier.doi10.1111/j.1537-2995.2006.00933.xen_US
dc.identifier.sourceTransfusionen_US
dc.identifier.citedreferenceDaniels G. Human blood groups. 2nd ed. Oxford: Blackwell Science; 2002.en_US
dc.identifier.citedreferenceReid ME, Powell V, Barnes J, et al. ZENA: a new high prevalence Cromer blood group antigen [abstract]. Transfusion 2004; 44 ( Suppl ): 26A.en_US
dc.identifier.citedreferenceStorry JR, Sausais L, Hue-Roye K, et al. GUTI: a new antigen in the Cromer blood group system. Transfusion 2003; 43: 340 - 4.en_US
dc.identifier.citedreferenceBanks J, Poole J, Ahrens N, et al. SERF. a new antigen in the Cromer blood group system. Transfus Med 2004; 14: 313 - 8.en_US
dc.identifier.citedreferenceStorry JR, Reid ME. The Cromer blood group system: a review. Immunohematology 2002; 18: 95 - 103.en_US
dc.identifier.citedreferenceIvankovic Z, Golubic Cepulic B, Bekavac M, et al. CROV: a new high prevalence Cromer blood group antigen. Transfusion 2005; 45 ( Suppl ): 122A.en_US
dc.identifier.citedreferenceLublin DM. Review: Cromer and DAF: role in health and disease. Immunohematology 2005; 21: 39 - 47.en_US
dc.identifier.citedreferenceRosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 1995; 86: 3277 - 86.en_US
dc.identifier.citedreferenceRosse WF, Nishimura J. Clinical manifestations of paroxysmal nocturnal hemoglobinuria. the present state and future problems. Int J Hematol 2003; 77: 113 - 20.en_US
dc.identifier.citedreferenceLevene C, Harel N, Lavie G, et al. A “new” phenotype confirming a relationship between Cr a and Tc a. Transfusion 1984; 24: 13 - 5.en_US
dc.identifier.citedreferenceLublin DM, Thompson ES, Green AM, Levene C, Telen MJ. Dr(a-) polymorphism of decay accelerating factor: biochemical, functional and molecular characterization and production of allele-specific transfectants. J Clin Invest 1991; 87: 1945 - 52.en_US
dc.identifier.citedreferenceReid ME, Mallinson G, Sim RB, et al. Biochemical studies on the red blood cells from a patient with the Inab phenotype (decay accelerating factor deficiency). Blood 1991; 78: 3291 - 7.en_US
dc.identifier.citedreferenceLublin DM, Mallinson G, Poole J, et al. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. Blood 1994; 84: 1276 - 82.en_US
dc.identifier.citedreferenceDaniels GL, Tohyama H, Uchikawa M. A possible null phenotype in the Cromer blood group complex. Transfusion 1982; 22: 362 - 3.en_US
dc.identifier.citedreferenceWalthers L, Salem M, Tessel J, et al. The Inab phenotype: another example found. Transfusion 1983; 23 ( Suppl ): 423.en_US
dc.identifier.citedreferenceLin RC, Herman J, Henry L, et al. A family showing inheritance of the Inab phenotype. Transfusion 1988; 28: 427 - 9.en_US
dc.identifier.citedreferenceWang L, Uchikawa M, Tsuneyama H, et al. Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group Inab phenotype. Blood 1998; 91: 680 - 4.en_US
dc.identifier.citedreferenceDaniels G, Green CA, Mallinson G, et al. Decay-accelerating factor (CD55) deficiency in Japanese. Transfus Med 1998; 8: 141 - 7.en_US
dc.identifier.citedreferenceUchikawa M, Tsuneyama H, Ogasawara K, et al. Another example of Inab phenotype in Japanese and production of human monoclonal anti-DAF. Vox Sang 2004; 87 ( S3 ): 41.en_US
dc.identifier.citedreferenceHue-Roye K, Powell VI, Patel G, et al. Novel molecular basis of an Inab phenotype. Immunohematology 2005; 21: 53 - 5.en_US
dc.identifier.citedreferenceMatthes T, Tullen E, Poole J, et al. Acquired and transient RBC CD55 deficiency (Inab phenotype) anti-IFC. Transfusion 2002; 42: 1448 - 57.en_US
dc.identifier.citedreferenceBanks J, Poole J, Prowse C, et al. Transient loss of Cromer antigens and anti-IFC in a patient with chronic lymphatic leukemia. Vox Sang 2004; 87 ( S3 ): 37.en_US
dc.identifier.citedreferenceJudd WJ. Methods in immunohematology. 2nd ed. Durham (NC): Montgomery Scientific Publications; 1994.en_US
dc.identifier.citedreferenceNowicki B, Moulds J, Hull R, et al. A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen. Infect Immun 1988; 56: 1057 - 60.en_US
dc.identifier.citedreferenceJudd WJ, Cooling L. Novel application of the gel test: detection of microbial-induced hemagglutination. Vox Sang 2004; 87 ( S3 ): 76.en_US
dc.identifier.citedreferenceTelen MJ, Rao N, Udani M, et al. Molecular mapping of the Cromer blood group Cr a and Tc a epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology. Blood 1994; 84: 3205 - 11.en_US
dc.identifier.citedreferenceMarsh WL, Nichols ME, Oyen R, et al. Naturally occurring anti-Kell stimulated by E. coli enterocolitis in a 20-day-old child. Transfusion 1978; 18: 149 - 54.en_US
dc.identifier.citedreferenceMedof ME, Walter EI, Rutgers JL, et al. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987; 165: 848 - 64.en_US
dc.identifier.citedreferenceLin F, Spencer D, Hatala DA, et al. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J Immunol 2004; 172: 3836 - 41.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.